Cellectar Biosciences, Inc. CLRB
Set alert
1.25 USD +0.03 +2.05%
As of Nov 3, 10:36 AM ET
1.23 Day range 1.26
1.12 52-week range 4.70
- YTD
- -57.80%
- 1 year
- -62.27%
- Open
- 1.24
- Prev close
- 1.22
- Mkt cap
- 11.77M
- Vol
- 25.40K
- Avg vol
- 87.09K
- EPS
- -3.46
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.23
- High
- 1.26
- Forward P/E
- -0.10
- Beta
- 1.01
- Short ratio
- 8.34
- Inst. own
- 34.55%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.60
- 200-d avg
- 2.48
- 1y target
- 5.67
MAX chart
Events in this range
- Mar 7, 2016Split: 1 for 10
- Nov 4, 2022Rating: HC Wainwright & Co. · — → Buy
- May 4, 2023Earnings: -0.76; estimate -0.75; surprise -1.33%
- Mar 4, 2024Rating: Roth MKM · Buy → Buy
Signals (38)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Jun 1, 2024 | 2 years ago |
| SMA: Bearish | Apr 1, 2024 | 2 years ago |
| SMA: Bullish | Feb 1, 2024 | 2 years ago |
| SMA: Bullish | Jun 1, 2023 | 3 years ago |
| SMA: Bearish | Sep 1, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bearish | Jun 1, 2021 | 5 years ago |
| SMA: Bearish | Jan 1, 2021 | 5 years ago |
| SMA: Bullish | Dec 1, 2020 | 5 years ago |
| SMA: Bullish | Dec 1, 2020 | 5 years ago |
| SMA: Bearish | Mar 1, 2020 | 6 years ago |
| SMA: Bullish | Dec 1, 2019 | 6 years ago |
| SMA: Bearish | Sep 1, 2019 | 7 years ago |
| SMA: Bullish | Jul 1, 2019 | 7 years ago |
| SMA: Bearish | Apr 1, 2017 | 9 years ago |
| SMA: Bullish | Mar 1, 2017 | 9 years ago |
| SMA: Bearish | Sep 1, 2015 | 11 years ago |
| SMA: Bullish | May 1, 2015 | 11 years ago |
| SMA: Bearish | Oct 1, 2012 | 14 years ago |
| SMA: Bullish | Apr 1, 2012 | 14 years ago |
Newest 20 of 38.
Analyst view
Consensus: buy
Buy
Price target (mean) 5.67 +355.2% upside
Now 1.25
- Target (low)
- 1.00
- Target (mean)
- 5.67
- Target (high)
- 13.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 3
- 2 months ago 3
- 3 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.3525 | -0.43 – -0.32 | -0.40 | +11.9% | 0 | 0.0% | 4 |
| Next quarter | -0.195 | -0.26 – -0.16 | -0.74 | +73.7% | 0 | 0.0% | 4 |
| Current year | -1.57 | -1.73 – -1.39 | -3.11 | +49.6% | 0 | 0.0% | 4 |
| Next year | -0.6825 | -0.77 – -0.63 | -1.57 | +56.5% | 10.09M | 0.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | Oppenheimer | Downgrade | Outperform | Perform |
| Nov 19, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 28, 2024 | Roth MKM | Maintained | Buy | Buy |
| Mar 28, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Mar 4, 2024 | Roth MKM | Reiterated | Buy | Buy |
| Nov 4, 2022 | HC Wainwright & Co. | Maintained | — | Buy |